Elizabeth Warren actually said...

"The GAO found that an emphasis on profits can lead private equity backed IRBs to rubber stamp reviews of drug clinical trials."

"According to a recent GAO report, despite representing just two percent of the review boards, these commercial IRBs now review over half of studies involving investigational new drugs."

"Now, while most IRBs are affiliated with universities, IRBs that are not associated with any institution, they are known as commercial IRBs, are reviewing a larger share of drug clinical trials."

"I want to say again thank you to Senator Braun for holding this hearing."